Neha Patil (Editor)

Ablynx

Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Covid-19
Traded as  ABLX
Website  www.ablynx.com
Founded  2002
Industry  Biotechnology
Headquarters  Ghent, Belgium
Ablynx wwwablynxcomassetsimagesablynxlogopng
Key people  Edwin Moses (CEO) Wim Ottevaere (CFO)
Stock price  ABLX (EBR) € 11.56 +0.04 (+0.39%)28 Feb, 3:59 PM GMT+1 - Disclaimer
Profiles
LinkedInYouTube

Ablynx


Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.

Contents

Ablynx received trends gazellen 2012 award


History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.

In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx. In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.

References

Ablynx Wikipedia


Similar Topics
The Glass Web
Joshua Malina
Jorge Casquilha
Topics
 
B
i
Link
H2
L